scholarly journals Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma

CHEST Journal ◽  
2015 ◽  
Vol 148 (3) ◽  
pp. 711-721 ◽  
Author(s):  
Kyuichi Kadota ◽  
Yi-Chen Yeh ◽  
Jonathan Villena-Vargas ◽  
Leonid Cherkassky ◽  
Esther N. Drill ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Lung Adenocarcinoma ◽  
Independent Prognostic Factor ◽  
Stage I ◽  
Tumor Budding ◽  
Immune Microenvironment

Transection of vaginal cuff is an independent prognostic factor in stage I endometrial cancer

2008 ◽  
Vol 34 (2) ◽  
pp. 241-246 ◽  
Author(s):  
H. Arndt-Miercke ◽  
A. Martin ◽  
V. Briese ◽  
R. Fietkau ◽  
B. Gerber ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Prognostic Factor ◽  
Independent Prognostic Factor ◽  
Stage I ◽  
Vaginal Cuff

D2-40-positive lymphatic vessel invasion is not a poor prognostic factor in stage I lung adenocarcinoma

2013 ◽  
Vol 63 (4) ◽  
pp. 201-205 ◽  
Author(s):  
Kei Shimizu ◽  
Kazuhito Funai ◽  
Haruhiko Sugimura ◽  
Keigo Sekihara ◽  
Akikazu Kawase ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Lung Adenocarcinoma ◽  
Lymphatic Vessel ◽  
Lymphatic Vessel Invasion ◽  
Stage I ◽  
Poor Prognostic Factor ◽  
Vessel Invasion

Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma

2006 ◽  
Vol 24 (34) ◽  
pp. 5414-5418 ◽  
Author(s):  
Sing-fai Leung ◽  
Benny Zee ◽  
Brigette B. Ma ◽  
Edwin P. Hui ◽  
Frankie Mo ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Nasopharyngeal Carcinoma ◽  
Early Stage ◽  
Independent Prognostic Factor ◽  
Stage I ◽  
Early Stage Disease ◽  
Stage Disease ◽  
Ebv Dna ◽  
Epstein Barr

Purpose To evaluate the effect of combining circulating Epstein-Barr viral (EBV) DNA load data with TNM staging data in pretherapy prognostication of nasopharyngeal carcinoma (NPC). Patients and Methods Three hundred seventy-six patients with all stages of NPC were studied. Pretreatment plasma/serum EBV DNA concentrations were quantified by a polymerase chain reaction assay. Determinants of overall survival were assessed by multivariate analysis. Survival probabilities of patient groups, segregated by clinical stage (I, II, III, or IV) alone and also according to EBV DNA load (low or high), were compared. Results Pretherapy circulating EBV DNA load is an independent prognostic factor for overall survival in NPC. Patients with early-stage disease were segregated by EBV DNA levels into a poor-risk subgroup with survival similar to that of stage III disease and a good-risk subgroup with survival similar to stage I disease. Conclusion Pretherapy circulating EBV DNA load is an independent prognostic factor to International Union Against Cancer (UICC) staging in NPC. Combined interpretation of EBV DNA data with UICC staging data leads to alteration of risk definition of patient subsets, with improved risk discrimination in early-stage disease. Validation studies are awaited.

scholarly journals Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor

2015 ◽  
Vol 10 (9) ◽  
pp. 1292-1300 ◽  
Author(s):  
Sai F. Yeung ◽  
Joanna H.M. Tong ◽  
Peggy P.W. Law ◽  
Lau Y. Chung ◽  
Raymond W.M. Lung ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Lung Adenocarcinoma ◽  
Independent Prognostic Factor ◽  
Oncogenic Driver

Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma

2006 ◽  
Vol 24 (5) ◽  
pp. 798-804 ◽  
Author(s):  
Henrik Schmidt ◽  
Julia S. Johansen ◽  
Pia Sjoegren ◽  
Ib J. Christensen ◽  
Boe S. Sorensen ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Serum Level ◽  
Independent Prognostic Factor ◽  
Stage I ◽  
Serum Samples ◽  
Primary Tumor Site ◽  
Ajcc Stage ◽  
American Joint Committee

PurposeTo evaluate the novel tumor biomarker YKL-40 in serial serum samples from patients with American Joint Committee on Cancer (AJCC) stage I and II melanoma from the time of diagnosis and during routine follow-up. Macrophages, neutrophils, and cancer cells secrete YKL-40, and a high serum level has been associated with poor prognosis in patients with several cancer types.Patients and MethodsSerum samples from 234 patients with stage I (n = 162) and II (n = 72) melanoma were analyzed for YKL-40 by enzyme-linked immunosorbent assay. Serial samples were obtained before definitive primary surgery and during follow-up.ResultsAfter a median follow-up period of 66 months (range, 1 to 97 months), 41 relapses (18%) and 39 deaths (17%) were observed. Serum YKL-40 treated as an updated continuous covariate were analyzed together with the covariates sex, age, primary tumor site, ulceration, thickness, Clark level and histologic subtype in a Cox proportional hazard model. Serum YKL-40 was an independent prognostic factor of relapse-free survival (hazard ratio [HR], 1.6; 95% CI, 1.1 to 2.5; P = .03) and overall survival (HR, 1.8; 95% CI, 1.2 to 2.6; P = .002) together with thickness and ulceration. The serum level of YKL-40 (dichotomized as normal or elevated) at the time of diagnosis was also an independent prognostic factor for overall survival (HR, 3.6, 95% CI, 1.7 to 7.7; P = .001).ConclusionSerum YKL-40 may be an early biomarker of relapse and survival in patients with AJCC stage I and II melanoma. Serum YKL-40 may also be useful for patient stratification and follow-up in clinical trials. Our results need confirmation in an independent study.

Sign in / Sign up

Export Citation Format

Share Document